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HISTORICAL CONTEXT
T he ability to develop discrete areas of tissue ﬁbro-sis or scarring represents a normal physiologicresponse to injury that is necessary for the main-
tenance of tissue integrity and normal organ function. In
contrast, uncontrolled, dysregulated ﬁbroproliferation and
abnormal matrix deposition/remodeling results in tissue
ﬁbrosis and organ dysfunction, regardless of the initiating
event.1 The latter process underlies a wide variety of clini-
cally signiﬁcant disorders ranging from idiopathic pulmo-
nary ﬁbrosis (IPF) and liver cirrhosis to kidney sclerosis
and cutaneous ﬁbrosis. However, the mechanisms
responsible for injury responses that lead to tissue ﬁbrosis
in these organs are incompletely understood. With an
enhanced understanding of the mechanisms responsible
for both physiologic and dysregulated ﬁbrosis across sev-
eral organ systems, common ﬁbrotic pathways may be
identiﬁed and potential targets for intervention can be
unveiled. Unfortunately, research in ﬁbrogenesis in distinct
organs has been conducted largely independently, with
very few examples of collaborative investigations into the
common and/or divergent pathways of tissue ﬁbrosis in
different organs. In the lung, for example, excessive ﬁbro-
proliferation and tissue remodeling can occur in response
to several deﬁned environmental and occupational
exposures or systemic illnesses. However, in idiopathic
pulmonary ﬁbrosis, the eliciting cause is unknown and the
mechanisms responsible for its progression are unclear,
but both genetic and environmental factors have been
implicated. Similar ﬁbrosing phenomena appear in other
organs, but whether there are shared or divergent mecha-
nisms of action among them remains uncertain.2-4
To promote collaboration and the exchange of infor-
mation amongst investigative teams focused on distinct
organs, the American Thoracic Society convened the
Fibrosis Across Organ Symposium with the intention of
deﬁning gaps in knowledge and priority areas for investi-
gation. The meeting was held in Denver, Colorado, USA,
in 2012, but the meeting proceedings were never pub-
lished. Considering the perceived importance of the
deliberations held, participants came together to sum-
marize the discussions in this document.
The organizers invited participants based on their
expertise in the investigation of ﬁbrogenesis as evi-
denced by their international reputation, publications
and presentations at international conferences. Partici-
pants with expertise in ﬁbrosis in lung, liver and heart,
among other organs, were asked to review topics rele-
vant to their area of expertise focusing on shared versus
organ-speciﬁc mechanisms of ﬁbrogenesis from which
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key insights may be gleaned. Prior to the conference,
participants were asked to identify and submit “5 Ques-
tions” which they would like to answer over the next
several years of investigation, and to rank them in order
of priority. These questions served as a template for
discussion in both the plenary sessions and in the
breakout, workshop sessions. This technique is a modi-
ﬁcation of the Delbecq nominal-group interactive
method, and ensures that all participants’ positions are
aired in an anonymous and/or open-forum fashion.5
This technique further ensures that all participants’
thoughts are equally considered in the breakout groups
and in the ﬁnal session where consensus recommenda-
tions are ﬁnalized by all participants. The following key
concepts of ﬁbrogenesis were explored: (1) mecha-
nisms of injury leading to ﬁbrosis, (2) mechanisms of
ﬁbroproliferation, (3) mechanisms of wound healing and
(4) mechanisms of antiﬁbrogenic therapies. Participants
with varied clinical and basic science backgrounds
were assigned to 1 of the 4 working groups focused on
these concepts. Each group was responsible for
reviewing our current knowledge, including in vitro and
in vivo model systems; identifying the important knowl-
edge gaps; and determining the critical “next ques-
tions” that need to be answered to allow progress,
while deﬁning short- and long-term research priorities.
Following the initial plenary sessions, participants broke
into 1 of 4 working groups based on the key concepts
and generated key priority questions considered critical
for exploration to advance the ﬁeld.
PRIORITIES AND GAPS IN KNOWLEDGE
IDENTIFIED
Working Group I—Mechanisms of Injury Leading to
Tissue Fibrosis
Although the speciﬁc tissue injury in some ﬁbrosing
disorders is known, many ﬁbroproliferative disorders are
idiopathic. This complicates the exploration of the mecha-
nisms leading to tissue ﬁbrosis. However, there is a general
sense that, while a variety of tissue injuries might trigger a
set of cellular signals common to multiple tissues and dis-
orders, other signals may be tissue or organ-speciﬁc, and
that studying these divergent pathways might provide
important insight.1 By the date of the symposium, there
had been limited systematic efforts designed to identify
signaling pathways or patterns of gene expression unique
to ﬁbrosis in speciﬁc organs, yet publicly available data
sets are available and can be interrogated for this purpose.
Priorities and Key Gaps of Knowledge
 What initiates the tissue injury in clinically signiﬁcant
diseases characterized by tissue ﬁbrosis?
 What proﬁbrogenic pathways are common among dif-
ferent organs?
 What proﬁbrogenic pathways are divergent among
different injured organs?
Working Group II—Mechanisms of Fibroproliferation
The fundamental mechanisms of ﬁbroproliferation
have been intensely investigated over the past several
decades. These efforts have implicated genetic predis-
position, cellular inﬂammation, tissue remodeling, oxida-
tive and endoplasmic reticulum stress, autophagy and
aging, among other mechanisms in the initiation and
propagation of ﬁbrosis.2,6 Models best suited to investi-
gate ﬁbroproliferation are evolving, but remain narrowly
deﬁned and context speciﬁc.
Priorities and Key Gaps of Knowledge
 What is the role of inﬂammation in tissue ﬁbrosis and
does it differ amongst organs?
 How does aging predispose individuals to ﬁbrosis?
 Which cellular components drive ﬁbroproliferation
during the early and late stages after injury, and from
where do they originate?
Working Group III—Mechanisms of Wound Healing
The response to injury, and more importantly its reso-
lution with minimal dysfunction, is an essential homeo-
static response regardless of the type and site of
injury.7,8 Signiﬁcant emphasis has been placed on the
initiating events leading to cellular and tissue injury due
to the available animal models.9 These models generally
fail to simulate human disease, which is often character-
ized by chronic and progressive ﬁbrosis. Additional
approaches which also emphasize the resolution phase
of injury might help accelerate our understanding of this
inherently complex process.
Priorities and Key Gaps of Knowledge
 What promotes adaptive vs. maladaptive wound heal-
ing during the reparative process triggered after
injury?
 What can be learned from comparing models of per-
manent versus reversible ﬁbrosis?
 Are there models of tissue ﬁbrosis that capture the
chronic and progressive ﬁbroproliferative disorders
seen in humans?
 Is ﬁbrosis permanent or can it be reversed, as seen in
fetal injuries and some disorders in adults?
Working Group IV—Mechanisms of Antiﬁbrogenic
Therapies
The identiﬁcation of efﬁcacious therapies for chronic
ﬁbrosing diseases has been challenging because of our
rudimentary understanding of the pathobiology of the
diseases in question.4 However, data generated in ani-
mal models and through clinical studies, and studies
using new genomic technologies, have unveiled obser-
vations that will inform future investigations particularly
in prognostication and novel therapies.10,11 These
approaches applied across different organ systems
might help identify common risk factors and mechanisms
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as well as potential targets for intervention. (Note that
antiﬁbrotic drugs approved for the management of IPF
emerged after this symposium was held.)
Priorities and Key Gaps of Knowledge
 What is the potential role of stem cells (e.g., iPS,
hematopoietic) and regulatory T cells in the develop-
ment and/or treatment of ﬁbrosis?
 Are there polymorphisms / epigenetic modiﬁcations
that predispose individuals to ﬁbrosis?
 How can the response to therapy be better assessed
clinically?
 Are there common biomarkers capable of deﬁning
degree or stage of ﬁbrosis?
 Are there imaging techniques able to quantify the
degree of ﬁbrosis and response to therapy?
PRIORITIES FOR FUTURE INVESTIGATION
Following the breakout sessions and identiﬁcation of
priority questions, the entire group developed the follow-
ing recommendations and identiﬁed opportunities for
future research directions.
 Develop a universal deﬁnition of ﬁbrosis that may be
applied to different tissues, including standard ways
to measure and grade degree of ﬁbrosis.
 Develop a systematic program to delineate the
mechanisms associated with aging that predispose
individuals to ﬁbrosis and organ dysfunction.
 Continue investigations into embryonic wound heal-
ing and the distinct differences that limit ﬁbrogenesis
in these tissues in contrast to those in adults.
 Determine how genetic and environmental factors
interact to predispose individuals to the develop-
ment of ﬁbrosis.
 Develop and validate novel models that more
robustly simulate human ﬁbrotic disease.
 Develop improved modalities to quantify ﬁbroprolif-
eration so that more durable and practical endpoints
of therapy can be utilized.
 Continue the identiﬁcation and validation of indirect
and direct biomarkers of ﬁbrotic diseases.
 Promote the development of a cellular and tissue
repository of ﬁbrotic tissue samples from multiple
organs to allow for rapid screening for potentially
“common” ﬁbrogenesis pathways.
 Develop an integrated approach for subcellular to tis-
sue level investigations, combined with translational
and clinical research to comprehensively investigate
the complex and shared processes that directly or
indirectly lead to signiﬁcant disability and death
related to ﬁbrosing disorders.
 Perform comparative analyses of molecular, genetic
and epigenetic data generated in organ speciﬁc
human ﬁbrosis.
 Establish an interdisciplinary “Fibrosis Network” of
investigators to identify common interests and expe-
dite investigations.
 Identify shared resources such as in vitro and in vivo
models of ﬁbrosis as well as reagents to facilitate
investigations.
 Convene a workshop to further interrogate potential
mechanisms of ﬁbrosis utilizing a comparative analy-
sis approach.
 Expand future Fibrosis Across Organs Symposia to a
more diverse ﬁeld of investigators with enhanced
representation from experts in quantitative imaging,
pathology and systems biology.
CONCLUSIONS
The goal of the 2012 Fibrosis Across Organs Sym-
posium was to identify important gaps in our knowledge
of ﬁbroproliferation, identify mechanisms shared across
or divergent among different organ systems, and estab-
lish a framework for research in the ﬁeld. At the time the
symposium was held, organizers believed the concept
would take hold in the scientiﬁc community and
become an area of focus in the years that followed.
Since the symposium, the Fibrosis Across Organs con-
cept has had some success in moving ﬁbrosis research
forward as several centers across the country now hold
regular meetings with their scientiﬁc experts in ﬁbrosis
across organs, collaborations have formed to carry out
novel research projects in multiple areas of ﬁbrotic dis-
ease, and new ﬁbrosis research centers are being cre-
ated. More recently, the National Heart, Lung and Blood
Institute of the National Institutes of Health published
its recommendations for the next decade of work in
lung ﬁbrosis and in its report identiﬁed ﬁbrosis across
organs as a priority area. In 2015, the NIH established a
new mechanism for research funding for Fibrosis
Across Organs representing $10.8 million in funding for
multiorgan ﬁbrosis projects until year 2020 (http://
grants.nih.gov/grants/guide/rfa-ﬁles/RFA-HL-16-003.
html). Although signs of progress driven by this effort
have emerged since the symposium, much more needs
to be done to take advantage of the knowledge gener-
ated through organ-speciﬁc tissue ﬁbrosis research
and accelerate discovery through collaborative initia-
tives. It is the expectation of the organizing team that
through an integrated approach and collaborative
efforts, the priorities for future investigation identiﬁed
above will be systematically addressed to advance our
understanding of and care for patients with devastating
organ ﬁbrosis.
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